Figure 1. Eligibility for Novel Therapies.

Eligibility for novel therapies to prevent atherosclerotic cardiovascular disease and death in patients with known ischemic heart disease (IHD) or prior myocardial infarction (MI) from a contemporary general population. A, Proportion eligible to receive at least 1 new secondary prevention medication. B, Eligibility by each trial individually ordered by drug classes. Data are based on individuals in the Copenhagen General Population Study.

^aLipid-modifying.

^bAntithrombotic.

^cAnti-inflammatory.

^dAntidiabetic.